Dr. Dormitzer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
320 Longwood Ave
# Enders
Boston, MA 02115Phone+1 617-355-3026
Summary
- Philip R. Dormitzer, M.D., Ph.D., is Head of US Research, Global Head of Virology, and Vice President at Novartis Vaccines and Diagnostics in Cambridge, Massachusetts. He is a practicing physician, board certified in Internal Medicine. After studying anthropology at Harvard College and carrying out a field study of the Efe Pygmies in the Ituri Forest of Zaire, Dr. Dormitzer completed his M.D. and Ph.D. degrees at Stanford University. His graduate research focused on rotavirus antigenic structure. Dr. Dormitzer completed house-staff training in Internal Medicine at Massachusetts General Hospital and a fellowship in the Harvard Combined Infectious Diseases Training Program. He conducted his fellowship research in the Laboratory of Molecular Medicine, led by Dr. Stephen Harrison. As an Assistant Professor of Pediatrics at Harvard Medical School, Dr. Dormitzer led a structural virology laboratory. The Dormitzer group and its collaborators determined the structures of the rotavirus neutralization antigens by NMR spectroscopy, X-ray crystallography, and near atomic resolution electron cryomicroscopy. At NV&D, as Senior Project Leader for Viral Vaccine Research, he had responsibility for global vaccine research projects on influenza, RSV, parvovirus B19, and other agents. In 2009, these projects included the research component of the Novartis response to the H1N1v influenza pandemic, supporting the development and licensure of three pandemic influenza vaccines in the most rapid vaccine response in history. As Head of the Viral Advanced Programs Global Team, he coordinated scientific and industrial functions to advance novel viral vaccine projects toward licensure, with a primary focus on an engineered RSV F subunit vaccine candidate, intended for maternal immunization. As Head of Research, US, he leads approximately 80 scientists, most based at the NV&D Cambridge Research Center, in their viral vaccine discovery mission.
Education & Training
- Harvard Combined Program in Infectious Diseases1996 - 2000
- Massachusetts General HospitalResidency, Internal Medicine, 1995 - 1996
- Massachusetts General HospitalInternship, Internal Medicine, 1994 - 1995
- Stanford University School of MedicineClass of 1994, MD
- Stanford University PhD, Cancer Biology, 1987 - 1992
- Harvard UniversityB.A., Biological Anthropology, summa cum laude, 1980 - 1986
Certifications & Licensure
- MA State Medical License 1996 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Maxwell Finland Award for scientific excellence during an infectious disease fellowship Massachusetts Infectious Disease Society, 2000
- Joseph Garrison Parker Prize for breadth of interest in a pre-medical student Harvard College, 1986
- Jacob Wendell Scholar for academic promise based on the record of the freshman year Harvard College, 1981
Publications & Presentations
PubMed
- 429 citationsBNT162b vaccines protect rhesus macaques from SARS-CoV-2.Annette B. Vogel, Isis Kanevsky, Ye Che, Kena A. Swanson, Alexander Muik
Nature. 2021-02-01 - 1254 citationsCOVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz
Nature. 2020-10-22 - 1004 citationsPhase I/II study of COVID-19 RNA vaccine BNT162b1 in adults.Mark J. Mulligan, Kirsten E. Lyke, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman
Nature. 2020-10-22
Journal Articles
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineFernando P Polack, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, Kenneth Koury, Robert W Frenck, Philip R Dormitzer, The New England Journal of Medicine
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine CandidatesEdward E Walsh, Robert W Frenck, Ann R Falsey, Judith Absalon, Kathleen Neuzil, Vanessa Raabe, Philip R Dormitzer, The New England Journal of Medicine
- Intra-Seasonal Antibody Repertoire Analysis of a Subject Immunized with an MF59®-Adjuvanted Pandemic 2009 H1N1 VaccineM Anthony Moody, Philip R Dormitzer, Stephen C Harrison, ScienceDirect
Books/Book Chapters
Press Mentions
- Maintaining Warp Speed: Policy Requirements for a Just-in-Time, Capability-Based, Scalable Medical Countermeasure Research and Development EnterpriseMay 18th, 2023
- IDSA Honors 175 Distinguished Physicians, Scientists with FIDSA DesignationAugust 17th, 2022
- COVID Vaccine Makers Prepare for a Variant Worse Than DeltaOctober 25th, 2021
- Join now to see all
Grant Support
- Synthetic Influenza Vaccine Seeds for Rapid Pandemic ResponseBiomedical Advanced Research and Development Authority2010–Present
- Manipulating Immunodominance In Influenza HANational Institute Of Allergy And Infectious Diseases2011
- Rotavirus Vp4: Structure And FunctionNational Institute Of Allergy And Infectious Diseases2003–2006
- Structural Basis For Rotavirus Entry Into CellsNational Institute Of Allergy And Infectious Diseases1998–2000
Committees
- Member, Research Committee, Infectious Diseases Society of America 2012 - Present
- Member, Editorial Board, Journal of Virology
Professional Memberships
- American Society for VirologyMember
- American Society for MicrobiologyMember
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: